Showing 61 - 80 of 118
-
-
Biden Administration鈥檚 Limit on Drug Industry Middlemen Backfires, Pharmacists Say
A rule taking effect Jan. 1 was intended to stop one set of abuses by pharmacy benefit managers, or PBMs, but some pharmacists say it鈥檚 enabling these price brokers to simply do new things unfairly.
By Arthur Allen -
Save Billions or Stick With Humira? Drug Brokers Steer Americans to the Costly Choice
Thousands of patients with autoimmune diseases who rely on Humira, with a list price of $6,600 a month, could get financial relief from new low-cost rivals. So far, the pharmacy benefit managers that control drug prices in America have not delivered on those savings.
By Arthur Allen -
Why the CDC Has Recommended New Covid Boosters for All
As covid-19 hospitalizations tick upward with fall approaching, the CDC says it鈥檚 time for new boosters 鈥 and not only for those at highest risk of serious disease. Here are seven things you need to know.
By Arthur Allen -
Pfizer and Moderna Are Pushing the New Covid Booster. Should You Get It? The CDC Is About to Decide.
Chances are, if you aren鈥檛 older, chronically ill, or obese, you don鈥檛 need a forthcoming covid vaccine to stay out of the hospital. But it probably wouldn鈥檛 hurt.
By Arthur Allen -
5 Things to Know About the New Drug Pricing Negotiations
The Biden administration unveiled the first 10 drugs subject to price negotiations, taking a swipe at the pharmaceutical industry. But what does it mean for patients?
-
The Real Costs of the New Alzheimer鈥檚 Drug, Most of Which Will Fall to Taxpayers
The annual cost of lecanemab treatment quadruples if the expense of brain scans to monitor for bleeds and other associated care is factored in. The full financial toll likely puts it beyond reach for low-income seniors at risk of Alzheimer鈥檚, experts say.
By Arthur Allen -
What You Need to Know About the Drug Price Fight in Those TV Ads
At least nine bills introduced in Congress take aim at pharmacy benefit managers, the powerful middlemen that channel prescription drugs to patients.
By Arthur Allen -
Why the Next Big Hope for Alzheimer鈥檚 Might Not Help Most Black Patients
Black patients and other minorities tend to be diagnosed at later stages of the disease, which would exclude them from use of Leqembi. Few Black people were included in the main trial of the drug.
By Arthur Allen -
Drugmakers Are Abandoning Cheap Generics, and Now US Cancer Patients Can鈥檛 Get Meds
A quality-control crisis at an Indian pharmaceutical factory has left doctors and their patients with impossible choices as cheap, effective, generic cancer drugs go out of stock.
By Arthur Allen -
A More Aggressive FTC Is Starting to Target Drug Mergers and Industry Middlemen
Industry analysts are skeptical that Federal Trade Commission Chair Lina Khan can win her first fight against a drug industry merger. It will be reviewed by a judge appointed by then-President Donald Trump.
By Arthur Allen -
PBMs, the Brokers Who Control Drug Prices, Finally Get Washington鈥檚 Attention
Drugmakers, pharmacies, and physicians blame pharmacy benefit managers for high drug prices. Congress is finally on board, too, but will it matter?
By Arthur Allen -
The Drug Company That Prospered Without Creating Any Drugs
Horizon Therapeutics, which Amgen is acquiring for about $28 billion, grew large by snapping up cheap drugs from other companies, marketing them to perfection, and jacking up prices.
By Arthur Allen -
Sen. Sanders Shows Fire, but Seeks Modest Goals, in His Debut Drug Hearing as Health Chair
The Vermont independent and former presidential candidate was all fire and brimstone at his first hearing on drug prices as head of the Senate HELP Committee. He also pursued a more modest goal of covid vaccine price reductions. It isn鈥檛 clear whether Sanders will succeed in even that, but he has put affordability front and center.
By Arthur Allen -
Why Does Insulin Cost So Much? Big Pharma Isn鈥檛 the Only Player Driving Prices
Big Pharma may be moving on from squeezing diabetes patients on insulin prices, but it鈥檚 the arbitrators that jack up prices for those who can least afford them.
By Arthur Allen -
鈥榃e Ain鈥檛 Gonna Get It鈥: Why Bernie Sanders Says His ‘Medicare for All’ Dream Must Wait
As he takes the reins of the Senate Health, Education, Labor & Pensions Committee, the independent from Vermont and implacable champion of 鈥淢edicare for All鈥 maps out his strategy for negotiating with Republicans 鈥 and Big Pharma.
By Arthur Allen -
Decisions by CVS and Optum Panicked Thousands of Their Sickest Patients
Pharmacy closures by two of the biggest home infusion companies point to grave shortages and dangers for patients who require IV nutrition to survive.
By Arthur Allen -
A Technicality Could Keep RSV Shots From Kids in Need
The Vaccines for Children program, which buys more than half the pediatric vaccines in the U.S., may not cover the RSV shot for babies because it鈥檚 not technically a vaccine.
By Arthur Allen -
FDA Experts Are Still Puzzled Over Who Should Get Which Covid Shots and When
A single booster seems to prevent death and hospitalization in most people, but protection from the current vaccines wanes within months. FDA experts say they need to know more from the Centers for Disease Control and Prevention to decide the best long-term strategy.
By Arthur Allen -
Is Legislation to Safeguard Americans Against Superbugs a Boondoggle or Breakthrough?
While supporters cheer the PASTEUR Act as an essential strategy to stem the rise of antibiotic-resistant pathogens, critics call it a multibillion-dollar giveaway to Big Pharma.
By Liz Szabo and Arthur Allen
Sign Up For Our Newsletter
Stay informed by signing up for the Morning Briefing and other emails: